Nanobiotix Appoints New Chief Medical Officer as the Company Evolves After Achievement of European Market Approval

Paris, France and Cambridge, Massachusetts, USA, Jun. 4 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it has appointed Edwina Baskin-Bey, M.D. as its new CMO. Dr. Baskin-Bey brings over 18 years of oncology clinical development and basic science experience [...]